Abstract：
Lipids interfere with absorbance measurements conducted using colorimetric methods. To monitor lipemia, some systems measure absorbance using an analyzer. This report describes a novel case of interference with the lipemia index without lipemia. A 64-year-old woman with giant basal cell carcinoma underwent resection and sentinel lymph node biopsy. The patient had been subcutaneously injected with patent blue during sentinel lymph node resection. After surgery, her serum and urine were yellow-green, and the lipemia index, calculated by measuring absorbance at 658 nm (main wavelength) and 694 nm (secondary wavelength) using a JCA-BM8040 chemistry analyzer, was high. The absorbance spectrum of the patient\'s serum and patent blue solution were compared to determine the cause of the high lipemia index. The patient\'s serum and the patent blue solution showed absorption at wavelengths between 540 and 698 nm. Moreover, the absorbance was concentration-dependent for patent blue. These results thus indicated that the patient\'s serum contained patent blue. Here, we report a case wherein patent blue affected the lipemia index. Thus, it must be noted that patent blue injection may yield inaccurate results when evaluating lipemia index.
摘要：
脂质干扰使用比色法进行的吸光度测量。为了监测血脂,一些系统使用分析仪测量吸光度。本报告描述了一种新的不伴有血脂的血脂指标干扰病例。一名64岁的巨大基底细胞癌妇女接受了切除和前哨淋巴结活检。在前哨淋巴结切除期间，患者已皮下注射专利蓝。手术后,她的血清和尿液呈黄绿色,和血脂指数，通过使用JCA-BM8040化学分析仪测量658nm（主波长）和694nm（次波长）处的吸光度来计算，很高。比较患者血清和专利蓝溶液的吸收光谱，以确定高脂血症指数的原因。患者血清和专利蓝溶液在波长540至698nm之间显示吸收。此外，专利蓝的吸光度是浓度依赖性的。因此,这些结果表明患者的血清含有专利蓝。这里,我们报告了一例专利蓝影响血脂指数的病例。因此，必须注意，在评估血脂指数时，专利蓝注射液可能会产生不准确的结果。
